A Phase 1b Study of TAK-659 in Combination With Venetoclax for Adult Patients With Previously Treated Non-Hodgkin Lymphoma
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs Mivavotinib (Primary) ; Venetoclax
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Takeda Oncology
- 14 Nov 2019 Planned primary completion date changed from 12 Jan 2020 to 12 Jun 2020.
- 14 Nov 2019 Status changed from recruiting to active, no longer recruiting.
- 23 Feb 2018 Status changed from not yet recruiting to recruiting.